VCNX Vaccinex Inc.

5.43
+0.29  (+6%)
Previous Close 5.14
Open 5.59
Price To Book -7.24
Market Cap 62313317
Shares 11,475,749
Volume 12,762
Short Ratio
Av. Daily Volume 14,897

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 cohort A publication of data due 2H 2019 with cohort B top-line data due 2H 2020.
VX15 - Signal
Huntington’s disease
Phase 1/2 completion estimated 2H 2020.
VX15 Yervoy and Opdivo
Melanoma
Phase 1/2 trial initial data due at ASCO 2019.
VX15 and avelumab
Non-small cell lung cancer (NSCLC)

Latest News

  1. Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
  2. Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
  3. Vaccinex, Inc. to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 19, 2019
  4. Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
  5. Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019
  6. Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington’s Disease (the “SIGNAL Trial”) at Cambridge Healthtech Institute’s 18th Annual PepTalk
  7. Vaccinex, Inc. Announces Completion of Enrollment for Its “SIGNAL” Huntington’s Disease Trial
  8. Do Insiders Own Lots Of Shares In Vaccinex, Inc. (NASDAQ:VCNX)?
  9. Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research
  10. Vaccinex, Inc. to Present at the 11th Annual LD Micro Main Event
  11. Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting
  12. Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  13. Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntington’s Disease at the Huntington Study Group’s 2018 Annual Meeting
  14. Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntington’s Disease
  15. Why Did Vaccinex Inc’s’ (NASDAQ:VCNX) Insiders Buy Up More Shares?
  16. Oppenheimer: Vaccinex Has Catalysts In Novel Therapies For Challenging Diseases